Navigation Links
Codexis Names Lori Giver VP Systems Biology
Date:3/31/2009

REDWOOD CITY, Calif., March 31 /PRNewswire/ -- Codexis, Inc. today announced Lori Giver, Ph.D., has been named to the new position of Vice President, Systems Biology for Codexis Bioindustrials. She is responsible for cellular engineering, molecular biology, and computational biology. Dr. Giver reports to David Anton, Ph.D., Vice President, Bioindustrials Research and Development.

Dr. Giver is a widely-respected researcher in the directed evolution of genes and proteins. She joined Codexis in 2002 from Maxygen, where she was responsible for biocatalyst discovery and development. At Codexis, she has held a series of scientific leadership roles ranging from Associate Director, Research & Development to her most recent position as Senior Director, Evolution Technology.

She received a bachelor's degree in molecular and cell biology from the University of California at Berkeley, and a Ph.D. in molecular, cell and developmental biology from Indiana University, Bloomington, where she focused on the directed evolution of nucleic acids with Dr. Andrew Ellington. Dr. Giver did post-doctoral research in directed evolution of proteins at the California Institute of Technology with advisor Dr. Frances Arnold, a pioneer in the field of directed evolution and biocatalysis.

"Lori Giver's contribution to the development of today's strong and broad Codexis technology platform has been invaluable," Dr. Anton said. "She is one of the original core team of scientists that built both our expertise in biocatalysis and our world-class reputation in this field. Her appointment recognizes the role that systems biology, in combination with biocatalysis, will play in finding solutions to the critical need for renewable fuels and future clean technology products. Lori's advancement to our senior scientific leadership team recognizes her strong personal and professional dedication to our company, to her colleagues, and to finding technology solutions to the major challenges facing our society."

Codexis, Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Teva in Licensing Agreement Final
2. Codexis Names Vice President, Intellectual Property
3. Codexis, Arch Announce Expanded Collaboration
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Names David Anton VP Bioindustrials R&D
6. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
7. Rothwell, Wolf Elected to Codexis Board
8. Codexis Opens Singapore Laboratory
9. Bruce Pasternack Elected to Codexis Board
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):